TBP (TSX) and MDC (ASX)

Both companies are investigating THC/CBD combinations for the the treatment of pain relief.

 

Currently, there remains a dire need for strong analgesics which can mimic the efficacy of opioids without addictive side effects. Mild analgesics such as aspirin or ibuprofen simply won't cut it for patients who are enduring sharp episodes of pain after surgery or have late stage cancer, or have neuropathic pain such as arthritis. 

There is ample evidence (available via a quick Pubmed search) suggesting the THC/CBD combination (nabiximols) is effective and accomplishing the said investigational goal. In fact, there has already been a drug approved (Sativex) which fulfills this purpose. 
 

Therefore, the argument for a sound investing thesis for both companies are as follows: 

-THC/CBD in roughly equivalent concentrations demonstrate effective pain relief when administered to patients

-The active ingredient in Tetra's CAUMZ/QIXLEEF and Medlab's NanaBis is exactly the same as the THC/CBD

-Therefore, both Tetra and Medlab may succeed in their clinical trials investigating cannibinoids for pain relief. 

I use the word "may" here as a precaution because the drugs can fail, here's where the risk comes from:

-THC/CBD in roughly equivalent concentrations demonstrate effective pain relief when administered to patients

-The active ingredient in Tetra's CAUMZ/QIXLEEF and Medlab's NanaBis is exactly the same as the THC/CBD, but demonstrate lower levels of absorption as nabiximols due to a different method of delivery. 

-Therefore, both Tetra and Medlab will fail their clinical trials investigating cannibinoids for pain relief if this scenario occurs.

PK data from Tetra shows inhaled CAUMZ/QIXLEEF did not come close to meeting the absorption level of nabiximols while vaporized CAUMZ/QIXLEEF did. As for MDC, there has yet been data released on the PK parameters of NanaBis. 

Caveat Emptor Ad Omnes...

                          ©2020 By Zhiyuan Sun. All Rights Reserved